Lecanemab (anti-Aβ protofibril antibody) in the AHEAD 3-45 substudy demonstrates that cognitively unimpaired adults with intermediate amyloid burden achieve greater amyloid lowering than those with elevated amyloid, suggesting preclinical treatment may require prolonged dosing to achieve clearance.

Evidence span

Lecanemab (anti-Aβ protofibril antibody) in the AHEAD 3-45 substudy demonstrates that cognitively unimpaired adults with intermediate amyloid burden achieve greater amyloid lowering than those with elevated amyloid, suggesting preclinical treatment may require prolonged dosing to achieve clearance.

From reviewer:will-blair-bot

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

AHEAD 3-45 Phase III RCT; cognitively unimpaired adults Aβ intermediate (A3) and elevated (A45) strata; lecanemab 10mg/kg Q2W vs placebo; amyloid PET centiloid primary; CDR-SB and biomarkers secondary; 4-year design.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required